Cancer Immunology – Products

Quell Therapeutics Ltd (“Quell” or “the Company”), and eXmoor pharma (“eXmoor”), announce a strategic partnership for the manufacture of multiple autologous engineered CAR-Treg cell therapies in Quell’s pipeline targeting autoimmune diseases.

Nona Biosciences, announced that it has entered into a multi-target antibody discovery collaboration with Umoja Biopharma. This collaboration leverages Nona's proprietary fully human heavy chain only antibody (HCAb) technology.

PHC Corporation’s Biomedical Division announced the commercial launch of LiCellMo, a live cell metabolic analyzer that allows researchers to visualize metabolic changes in cell cultures.

This whitepaper explores the available technologies, key challenges and the growing impact of single-cell cloning.

This application note highlights the features of active-release beads compared to the established passive-release beads for the isolation, activation, cell expansion and desired early memory cell phenotype.

Transgene announces the publication in the Journal for ImmunoTherapy of Cancer (JITC) of a peer-reviewed article which illustrates that TG6050 induces profound immune remodeling of the tumor microenvironment in animal models.

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency.

This article explores how cell-to-cell communication can be targeted for novel treatment methods.

Transgene (Euronext Paris: TNG), announces the conversion into equity of 32,999,999.57 euros of debt, drawn down under the outstanding current account advance with its majority shareholder TSGH.

New service enables identification of bispecific antibody candidates accelerating drug development.